摘要
目的探讨肿瘤增殖抗原(Ki67)及微小染色体维持蛋白(MCM)MCM-6在弥漫大B细胞淋巴瘤(DLBCL)中的表达及其与预后的关系。方法选取48例DLBCL患者,采用免疫组化方法检测患者Ki67及MCM-6的表达,分析其与DLBCL临床特征、疗效及预后的关系。结果 Ki67及MCM-6的表达与生存显著相关,低表达/高表达组相比较,其平均生存期(月)分别为:Ki67:57.46/32.32(P=0.038),MCM-6:64.50/39.05(P=0.047)。且MCM-6阳性高表达率明显高于Ki67(64.58%/33.33%,P=0.002<0.01)。结论 Ki67、MCM-6低表达组的患者其生存期均明显优于高表达组,Ki67及MCM-6是DLBCL良好的预后相关的分子标志物,且MCM-6更优于Ki67。
Objective To elucidate the prognostic relevance of Ki67 and MCM - 6 in patients with diffuse large - B - cell lymphoma. Methods 48 cases of primarily diagnosed DLBCL were included into this study. The expressions of Ki67 and MCM - 6 were analyzed by the im- munohistochemistry stain. Results Ki67, MCM - 6 positive rate were 97.92% and 95.83% respectively. Ki67 and MCM - 6 expression was as- sociated with a significant survival and overall survival （OS）. The average survival period of low expression group is obviously better than the high expression group. The high positive expression rate of MCM - 6 is significantly higher than that of Ki67. Conclusion Poor survival in DLBCL was clearly predicted in patients who demonstrated high expression of CIM4 - V6, MCM -6 and Ki67. MCM6 seems to be a predictor of survival, which is superior to the Ki -67 antigen.
出处
《临床和实验医学杂志》
2013年第23期1880-1884,共5页
Journal of Clinical and Experimental Medicine
